{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:26:22Z","timestamp":1794576382323,"version":"4.9.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atrial fibrillation (AF) is a common cardiac arrhythmia associated with a high risk of thrombo-embolic events, such as ischaemic stroke and systemic embolism, which require anticoagulant treatment. Vitamin K antagonists and direct oral anticoagulants represent the current therapeutic standards, but they are limited by the risk of bleeding. In this scenario, factor XI (FXI) inhibitors are emerging as a new therapeutic option, potentially capable of reducing bleeding risk while maintaining antithrombotic efficacy. Molecules such as abelacimab, asundexian, and milvexian are under investigation for the prevention of thrombo-embolic events in patients with AF. Although preliminary data on these compounds suggest a favourable safety profile, the results regarding efficacy do not yet appear convincing. The phase 2 AZALEA-TIMI 71 trial was prematurely terminated after demonstrating a clear reduction in the incidence of major bleeding with abelacimab compared to rivaroxaban, whereas the phase 3 OCEANIC-AF study on asundexian was stopped due to inferiority compared to apixaban. Ongoing trials, such as LILAC-TIMI 76 and LIBREXIA-AF, are crucial to confirm the efficacy and safety of this therapeutic class. While FXI inhibitors represent a potential breakthrough in the treatment of AF, further data are needed to determine their definitive role in clinical practice.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suaf015","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:24:20Z","timestamp":1744813460000},"page":"iii46-iii53","source":"Crossref","is-referenced-by-count":8,"title":["Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start?"],"prefix":"10.1093","volume":"27","author":[{"given":"Carmelo","family":"Raffo","sequence":"first","affiliation":[{"name":"Cardiovascular Department, A.O.U. Policlinico \u2018G. Rodolico\u2014San Marco\u2019, University of Catania , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacinto","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, A.O.U. Policlinico \u2018G. Rodolico\u2014San Marco\u2019, University of Catania , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, A.O.U. Policlinico \u2018G. Rodolico\u2014San Marco\u2019, University of Catania , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2025041610241434800_suaf015-B1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jacc.2020.02.025","article-title":"Atrial fibrillation: JACC council perspectives","volume":"75","author":"Chung","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025041610241434800_suaf015-B2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025041610241434800_suaf015-B3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2025041610241434800_suaf015-B4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2025041610241434800_suaf015-B5","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1093\/eurheartj\/ehac587","article-title":"Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing","volume":"43","author":"Meyre","year":"2022","journal-title":"Eur Heart J"},{"key":"2025041610241434800_suaf015-B6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur Heart J"},{"key":"2025041610241434800_suaf015-B7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041610241434800_suaf015-B8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025041610241434800_suaf015-B9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2025041610241434800_suaf015-B10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"2025041610241434800_suaf015-B11","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1016\/j.jacc.2021.04.053","article-title":"Preventing and managing bleeding with anticoagulation for atrial fibrillation","volume":"77","author":"Granger","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025041610241434800_suaf015-B12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacep.2017.04.024","article-title":"Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke","volume":"3","author":"Redfors","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"key":"2025041610241434800_suaf015-B13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","volume":"84","author":"Galli","year":"2024","journal-title":"Drugs"},{"key":"2025041610241434800_suaf015-B14","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/eurheartjsupp\/suae013","article-title":"Factor XI inhibition in patients with acute coronary syndrome","volume":"26","author":"Raffo","year":"2024","journal-title":"Eur Heart J Suppl"},{"key":"2025041610241434800_suaf015-B15","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5683.23.06474-8","article-title":"Future of factor XI inhibitors in cardiovascular practice","author":"Greco","year":"2024","journal-title":"Minerva Cardiol Angiol"},{"key":"2025041610241434800_suaf015-B16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"2025041610241434800_suaf015-B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2025041610241434800_suaf015-B18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"2025041610241434800_suaf015-B19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"2025041610241434800_suaf015-B20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"2025041610241434800_suaf015-B21","article-title":"In the wake of OCEANIC-AF, is equipoise regarding factor XI inhibition still afloat?","author":"Gibson","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_3\/iii46\/62939299\/suaf015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_3\/iii46\/62939299\/suaf015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:24:23Z","timestamp":1744813463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_3\/iii46\/8114518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,4,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suaf015","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}